Background
Neoadjuvant chemotherapy is an essential therapeutic approach for patients with breast cancer, with the goal of improving pathological complete response rate (pCR) by decreasing staging and evaluating treatment response for prognostic purposes. Proliferation index estimated by Ki67 has a significant effect on tumor prognosis with a cutoff value of 30%. However, data are still insufficient about the predictive cutoff value for pCR after neoadjuvant chemotherapy. The objective of this study was to evaluate the pathologic response after neoadjuvant chemotherapy in patients with breast cancer, to examine the effect of Ki67 index on the rate of pathologic response with the estimation of the proper predictive cutoff value. We also studied the correlation of the pCR rate with different prognostic histopathological parameters.
Patients and methods
The study included 84 patients with breast cancer who received neoadjuvant chemotherapy. Baseline Ki67 immunohistochemical expression was evaluated.
Results
Overall, 25% of the patients achieved pCR. The optimal cutoff point for Ki67 was 25%. There is a significant correlation between pCR and tumor-infiltrating lymphocytes (TILs), T stage before therapy, lymph node metastasis, and postmenopausal state. Linear regression analysis showed that Ki67 and TILs were associated with an increased rate of pCR after neoadjuvant therapy with a highly significant correlation.
Conclusion
In patients with breast cancer, Ki67 expression with a cutoff threshold of 25% could be used to predict the probability of achieving a complete response to neoadjuvant therapy. TILs are strongly associated with pCR.